Search

In this paper, we describe an automated, high-throughput analytical tool for the unambiguous characterization of the active component(s) of a combinatorially derived reaction mixture. We call this technique high-throughput bioassay-guided fractionation (BGF). The novel aspects of this communication are the systematization of the BGF concept, the application of BGF to combinatorial chemistry, and the high-throughput nature of the identification technique. The identification of the active component in a well mixture is an essential step for subsequent resynthesis or isolation of the active component(s) or for removal of intractable wells from further consideration. We believe the technique described is also applicable to any mixture library, provided the expected component (or components) of each well is (are) known. Example mixture libraries would include collections of synthetic chemicals and collections of purified natural products. The mixture need not come from libraries produced using parallel synthesis. The BGF tool described herein allows full utilization of highly diverse combinatorial libraries, thereby obviating costly up-front purification or extensive prescreening characterization efforts.

Purpose. The expression of cytochrome P450 enzymes (CYPs) in animals and humans is under complex hormonal regulation. Chronic treatment with drugs that alter sex hormone levels such as GnRH receptor agonists or antagonists may affect the expression of hormone-dependent CYPs, and as a result the pharmacokinetics of drugs metabolized by them. Methods. Enzyme kinetic parameters were obtained by incubating AG-045572 (0.1-30 μM) with human or rat liver microsomes, or expressed CYP3A4 and CYP3A5. The pharmacokinetics of AG-045572 (10 mg/kg i.v. or 20 mg/kg p.o.) were studied in intact male, female, castrated male and male rats pretreated with AG-045572 for 4 days. Results. AG-045572 is metabolized by CYP3A in both rats and humans. The Km values were similar in male and female human, female rat liver microsomes, and expressed CYP3A4 and CYP3A5 (0.39, 0.27, 0.28, 0.25, and 0.26 μM, respectively). The Km in male rat liver microsomes was 1.5 μM, suggesting that in male and female rats AG-045572 is metabolized by different CYP3A isozymes. The oral bioavailability of AG-045572 in intact male rats was 8%, while in female or castrated male rats it was 24%. Pretreatment of intact male rats with AG-045572 i.m. for 4 days resulted in suppression of testosterone to castrate levels, accompanied by an increase in oral bioavailability of AG-045572 to 27%. In the same experiment, the male-specific pulsatile pattern of growth hormone remained unchanged with slightly elevated baseline levels. Conclusions. The potent GnRH receptor antagonist AG-045572 is metabolized by hormone-dependent CYP3A. As a result, suppression of testosterone by pretreatment with AG-045572 “feminized” its own pharmacokinetics.

To improve the analytical usefulness of Fourier transform ion cyclotron resonance mass spectrometry (FTICR-MS), an extensive survey of various methods for quantitation of peak magnitudes has been undertaken using a series of simulated transient response signals with varying signal-to-noise ratio. Both peak height (five methods) and peak area (four methods) were explored for a range of conditions to determine the optimum methodology for quantitation. Variables included dataset size, apodization function, damping constant, and zero filling. Based on the results obtained, recommended procedures for optimal quantitation include: apodization using a function appropriate for the peak height ratios observed in the spectrum (i.e., Hanning for ratios of about 1:10, three-term Blackman-Harris for ratios of ∼1:100, or Kaiser-Bessel for ratios of ∼1:1000); zero filling until the peaks of interest are represented by 10–15 points (generally obtained with one order of zero filling); and use of the polynomial y = (ax2 + bx + c)n and the three data points of highest intensity of the peak to locate the peak maximum, Ymax = (−b2/4a + c)n. In this peak fitting procedure, which we have termed the “Comisarow method,” n is 5.5, 9.5, and 12.5 for the Hanning, three-term Blackman-Harris, and Kaiser-Bessel apodization functions, respectively. Accuracy of quantitation using an optimal peak height determination is about equal to that for peak area measurements. These recommendations were found to be valid when tested with real FTICR-MS spectra of xenon isotopes.

Initial results obtained by incorporation of an inductively coupled plasma (ICP) ion source with a Fourier transform ion cyclotron resonance (FTICR) mass spectrometer are reported, along with spectra which demonstrate sub-milligram-per-liter detection limits and high mass resolution (mass resolving power, m/Δm10%V = 7000−10 000). Also shown is an ICP-FTICR spectrum with ultrahigh resolving power (m/Δm10%V = 88 000). Both instrumental configurations used to conduct this work, one at the University of Florida, and the other at the National High Magnetic Field Laboratory, are described. Also included are concise results from a computer aided interference study designed to enumerate mass spectral interferences requiring mass resolving power in excess of 10 000.

The expression of cytochrome P450 enzymes (CYPs) in animals and humans is under complex hormonal regulation. Chronic treatment with drugs that alter sex hormone levels such as GnRH receptor agonists or antagonists may affect the expression of hormone-dependent CYPs, and as a result the pharmacokinetics of drugs metabolized by them.Enzyme kinetic parameters were obtained by incubating AG-045572 (0.1-30 microM) with human or rat liver microsomes, or expressed CYP3A4 and CYP3A5. The pharmacokinetics of AG-045572 (10 mg/kg i.v. or 20 mg/kg p.o.) were studied in intact male, female, castrated male and male rats pretreated with AG-045572 for 4 days.AG-045572 is metabolized by CYP3A in both rats and humans. The Km values were similar in male and female human, female rat liver microsomes, and expressed CYP3A4 and CYP3A5 (0.39, 0.27, 0.28, 0.25, and 0.26 microM, respectively). The Km in male rat liver microsomes was 1.5 microM, suggesting that in male and female rats AG-045572 is metabolized by different CYP3A isozymes. The oral bioavailability of AG-045572 in intact male rats was 8%, while in female or castrated male rats it was 24%. Pretreatment of intact male rats with AG-045572 i.m. for 4 days resulted in suppression of testosterone to castrate levels, accompanied by an increase in oral bioavailability of AG-045572 to 27%. In the same experiment, the male-specific pulsatile pattern of growth hormone remained unchanged with slightly elevated baseline levels.The potent GnRH receptor antagonist AG-045572 is metabolized by hormone-dependent CYP3A. As a result, suppression of testosterone by pretreatment with AG-045572 "feminized" its own pharmacokinetics.